Northern Leaf
Northern Leaf is a Jersey-based, EU-GMP-certified medical cannabis cultivator that produces pharmaceutical-grade cannabis for export to UK and European pharmaceutical distributors. The company operates on a pre-sold B2B model, exporting approximately 6 tons annually with planned expansion to 9 tons.
- Company typePrivate
- Founded2019
- HeadquartersSt. Helier
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Northern Leaf does
Northern Leaf is a Jersey-based medical cannabis cultivator operating under a bulk EU-GMP licence, producing pharmaceutical-grade cannabis for export to UK and European pharmaceutical supply chains. Founded in the wake of Jersey's 2017 regulatory changes permitting medicinal cannabis cultivation, the company utilizes repurposed greenhouses on the island as its primary production infrastructure and is positioned as a major employer within Jersey's nascent biopharmaceutical sector, which collectively employs approximately 70 people.
Northern Leaf firmographics
Firmographics- Name
- Northern Leaf
- Legal name
- Northern Leaf
- Website
- https://northern-leaf.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Northern Leaf is a Jersey-based, EU-GMP-certified medical cannabis cultivator that produces pharmaceutical-grade cannabis for export to UK and European pharmaceutical distributors. The company operates on a pre-sold B2B model, exporting approximately 6 tons annually with planned expansion to 9 tons.
- Ownership category
- akta.pro rank
Northern Leaf industry classification
Industry- Product category
- Medical Cannabis Cultivation
- NAICS
- Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Cannabis Wholesale Distribution (Flower, Extracts, Edibles) (CRAOAIAF)
Keywords
Where Northern Leaf is headquartered
LocationHeadquarters
- HQ city
- St. Helier
Offices1 record
Markets served
Northern Leaf business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Others
Revenue model
- Medical Cannabis Product Sales: Northern Leaf generates revenue through the production and sale of medical cannabis to pharmaceutical supply chains. The company exports cannabis products to UK and European pharmaceutical markets. All production over the past five months has been sold, and future harvests are pre-sold into target markets, indicating a strong demand-driven revenue model with contracted sales.
Go-to-market motion1 record
Distribution channels2 records
Northern Leaf product offering
Product offeringCore offering
Northern Leaf cultivates and produces pharmaceutical-grade medical cannabis in Jersey under a bulk EU-GMP licence. The company exports approximately 6 tons of medical cannabis in 2025 with plans to increase to 9 tons in 2026, supplying UK and European pharmaceutical companies and distributors. All recent production has been pre-sold into target markets, indicating contracted B2B supply relationships.
Product overview
Northern Leaf operates as a single-product medical cannabis company focused on cultivation and production of pharmaceutical-grade cannabis. The company holds a bulk EU-GMP licence enabling it to supply the UK and European pharmaceutical markets. All production is pre-sold into target markets, with the company exporting approximately six tons annually and planning to increase to nine tons in subsequent years. The core product is the medical cannabis production output itself, which serves the regulated pharmaceutical supply chain.
Differentiator
Problem solved
Functional benefit
Products and services
- Medical Cannabis Production Cultivation and production of pharmaceutical-grade medical cannabis under a bulk EU-GMP licence for export to UK and European pharmaceutical supply chains. Operating from repurposed greenhouses in Jersey, with production scaled to approximately 6 tons in 2025 and planned 9 tons in 2026.
Companies that use Northern Leaf
Customer profileSegments1 record
Ideal customer profiles1 record
Northern Leaf technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Northern Leaf partnerships and signals
Strategic signalScale indicators5 records
Recent moves5 records
Expansion highlights3 records
Northern Leaf competitors and assessment
Company assessmentBroad incumbents
- Tilray Brands: Large global cannabis company with significant medical cannabis operations in Europe, including Portugal-based cultivation and EU-GMP certified production. Comparable to Northern Leaf as a competing supplier of EU-GMP certified medical cannabis to European pharmaceutical supply chains, but at vastly greater scale and broader product range.
- Aurora Cannabis: Major Canadian-listed cannabis producer with EU-GMP facilities in Europe supplying medical cannabis to UK and German markets. Comparable as a competing EU-GMP-certified bulk medical cannabis exporter, though Aurora operates at significantly larger scale with a broader product portfolio.
- Canopy Growth: Global cannabis producer with medical cannabis operations across Europe, including Spectrum Therapeutics. Comparable to Northern Leaf in targeting the UK and European medical cannabis supply chains with EU-GMP certified product, but with much broader geographic reach and product range.
- Curaleaf International: Operates one of the largest EU-GMP certified medical cannabis production facilities in Europe (Portugal) and supplies pharmaceutical distributors across the UK and EU. Direct comparable to Northern Leaf in product category (EU-GMP bulk medical cannabis) and customer base, but at much greater scale.
Direct peers
- OrganiGram Holdings: Canadian cannabis producer that has invested in EU-GMP certified production (Germany) to supply the European medical cannabis market. Comparable to Northern Leaf in business model (EU-GMP certified bulk medical cannabis exporter to European pharma supply chains).
- Little Green Pharma: Australian medical cannabis producer with EU-GMP certified Danish operations supplying European pharmaceutical markets. Highly comparable to Northern Leaf as a smaller-scale EU-GMP certified medical cannabis exporter focused on European B2B pharmaceutical supply chains.
- Demecan: German medical cannabis producer holding a domestic cultivation licence and supplying the German and broader European pharmaceutical market. Comparable to Northern Leaf as a regional EU-GMP certified medical cannabis cultivator serving European pharmaceutical supply chains.
- Bedrocan: Dutch medical cannabis producer with decades of experience supplying pharmaceutical-grade cannabis to European markets under strict regulatory frameworks. Comparable to Northern Leaf in product category (EU-GMP-equivalent pharmaceutical grade medical cannabis) and customer base, though Bedrocan is a long-established incumbent.
- Stenocare: Danish medical cannabis company supplying pharmaceutical-grade products to European markets, including through B2B distribution. Comparable to Northern Leaf as a smaller European medical cannabis producer targeting pharmaceutical supply chains.
Emerging players
- Wayland Group / ICC International Cannabis Corp: European-focused medical cannabis operator with EU-GMP certified production assets supplying pharmaceutical distributors across the UK and EU. Comparable to Northern Leaf in targeting the same UK/European pharmaceutical B2B market with EU-GMP certified product.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
Northern Leaf compliance and trust
Trust signalCompliance1 record
Northern Leaf financial estimates
Financial estimateRevenue estimate
Valuation estimate
Northern Leaf leadership team
Management profileNumber of profiles
Northern Leaf funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Northern Leaf M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Northern Leaf
What does Northern Leaf do?
Northern Leaf cultivates and produces pharmaceutical-grade medical cannabis in Jersey under a bulk EU-GMP licence. The company exports approximately 6 tons of medical cannabis in 2025 with plans to increase to 9 tons in 2026, supplying UK and European pharmaceutical companies and distributors. All recent production has been pre-sold into target markets, indicating contracted B2B supply relationships.
Is Northern Leaf a public or private company?
Northern Leaf is a private company. It is classified as venture growth investor backed and is currently operating.
When was Northern Leaf founded?
Northern Leaf was founded in 2019. It employs 11 to 50 people.
Where is Northern Leaf based?
Northern Leaf is headquartered in St. Helier.
How does Northern Leaf make money?
One revenue line is on record: medical Cannabis Product Sales.
Who are Northern Leaf's main competitors?
Broad incumbents on record are Tilray Brands, Aurora Cannabis, Canopy Growth and Curaleaf International. Direct peers are OrganiGram Holdings, Little Green Pharma, Demecan, Bedrocan and Stenocare. Wayland Group / ICC International Cannabis Corp is listed as an emerging player.
Does Northern Leaf have an API?
No public API is recorded for Northern Leaf.
What industry is Northern Leaf in?
Northern Leaf's product category is Medical Cannabis Cultivation. Its primary akta.pro industry code is CRAOAIAF, Cannabis Wholesale Distribution (Flower, Extracts, Edibles). Its NAICS code is 325411 and its SIC code is 2833.